ARVN

Insider Trades

Name	Value	Action	Price	Current Price
Teel RandyDirector, Officer: President And CEO $20k2.2k shares SellMay 21, 2026 $9.04 --
Berkowitz NoahChief Medical Officer $110k11.1k shares SellMay 11, 2026 $9.94 --
Saik AndrewChief Financial Officer $111k11.1k shares SellMay 11, 2026 $9.94 --
Cacace Angela MChief Scientific Officer $96k9.7k shares SellMay 11, 2026 $9.94 --
Teel RandyDirector, Officer: President And CEO $96k9.7k shares SellMay 11, 2026 $9.94 --
Loomis David KVP, Chief Accounting Officer $19k1.9k shares SellMay 11, 2026 $9.94 --

News

marketbeat.comArvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Datamarketbeat.comJun 5

globenewswire.comArvinas to Present at Jefferies Global Healthcare Conferenceglobenewswire.comMay 29

globenewswire.comArvinas Employees Give Back During Company-wide Impact Dayglobenewswire.comMay 18

benzinga.comThese Analysts Increase Their Forecasts On Arvinas After Q1 Resultsbenzinga.comMay 13

Trade ARVN

About Arvinas, Inc.

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.

CEO: Randy Teel
IPO Date: Sep 27, 2018

Market Data

Open: $7.71
High: $7.81
Low: $7.40
Volume: 631.3K
52W High: $14.51
52W Low: $6.06

Valuation

Market Cap: $479M
Enterprise Value: $400M

Financials

Free Cash Flow: $-276M
Revenue: $263M
Net Income: $-81M
Cash: $143M
Debt: $8.9M

Events

EarningsAug 5

EPS est. -0.24